(CercleFinance.com) – Merck’s KEYTRUDA ® (pembrolizumab) plus chemotherapy treatment met the primary endpoint of progression-free survival (PFS) as a first-line treatment for advanced or recurrent endometrial carcinoma.
‘KEYTRUDA and chemotherapy significantly improved progression-free survival compared to standard chemotherapy alone as first-line treatment for patients with stage III-IV or recurrent endometrial carcinoma,’ the group states.
In a pre-specified interim analysis conducted by an independent data monitoring committee, KEYTRUDA, in combination with chemotherapy and then continued as monotherapy every six weeks for up to 14 cycles, demonstrated statistically significant and clinically meaningful improvement of PFS compared to chemotherapy alone.
‘Patients with advanced or recurrent endometrial cancer, the most common type of gynecological cancer in the United States, face a poor prognosis and limited treatment options,’ said the Dr. Ramez Eskander, principal investigator and gynecological oncologist at the University of California, San Diego.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
